Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 50,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was purchased at an average cost of $1.56 per share, for a total transaction of $78,000.00. Following the completion of the acquisition, the chief executive officer now owns 3,068,951 shares in the company, valued at $4,787,563.56. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Tuesday, November 26th, Phillip Md Et Al Frost acquired 100,000 shares of Opko Health stock. The shares were purchased at an average price of $1.55 per share, for a total transaction of $155,000.00.
  • On Monday, November 18th, Phillip Md Et Al Frost bought 100,000 shares of Opko Health stock. The shares were purchased at an average cost of $1.48 per share, with a total value of $148,000.00.
  • On Tuesday, November 12th, Phillip Md Et Al Frost bought 200,000 shares of Opko Health stock. The stock was acquired at an average cost of $1.44 per share, with a total value of $288,000.00.
  • On Friday, November 8th, Phillip Md Et Al Frost bought 50,000 shares of Opko Health stock. The stock was acquired at an average cost of $1.48 per share, with a total value of $74,000.00.
  • On Wednesday, November 6th, Phillip Md Et Al Frost purchased 350,000 shares of Opko Health stock. The stock was acquired at an average price of $1.49 per share, for a total transaction of $521,500.00.
  • On Thursday, October 31st, Phillip Md Et Al Frost purchased 50,000 shares of Opko Health stock. The shares were acquired at an average cost of $1.43 per share, for a total transaction of $71,500.00.
  • On Tuesday, October 29th, Phillip Md Et Al Frost acquired 200,000 shares of Opko Health stock. The stock was acquired at an average price of $1.47 per share, with a total value of $294,000.00.
  • On Friday, October 25th, Phillip Md Et Al Frost acquired 2,000,000 shares of Opko Health stock. The stock was acquired at an average price of $1.50 per share, with a total value of $3,000,000.00.

Shares of OPK traded down $0.01 during trading hours on Tuesday, hitting $1.55. 29,292 shares of the company were exchanged, compared to its average volume of 4,960,268. The company has a quick ratio of 0.90, a current ratio of 1.08 and a debt-to-equity ratio of 0.14. Opko Health Inc. has a fifty-two week low of $1.33 and a fifty-two week high of $3.93. The company has a market cap of $1.04 billion, a price-to-earnings ratio of -6.24 and a beta of 2.20. The firm’s fifty day moving average is $1.64 and its 200 day moving average is $1.93.

Opko Health (NASDAQ:OPK) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.11) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.02). Opko Health had a negative net margin of 30.98% and a negative return on equity of 14.42%. The company had revenue of $228.80 million during the quarter, compared to analyst estimates of $225.40 million. During the same period last year, the firm earned ($0.05) EPS. The firm’s revenue for the quarter was down 8.4% compared to the same quarter last year. Analysts anticipate that Opko Health Inc. will post -0.43 EPS for the current year.

OPK has been the topic of a number of analyst reports. Barrington Research restated a “buy” rating and set a $4.00 target price on shares of Opko Health in a research report on Thursday, September 12th. Piper Jaffray Companies began coverage on shares of Opko Health in a report on Monday, November 25th. They set an “overweight” rating and a $2.50 target price on the stock. Zacks Investment Research upgraded shares of Opko Health from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research report on Friday, October 18th. Finally, BidaskClub upgraded Opko Health from a “sell” rating to a “hold” rating in a research note on Thursday, November 21st. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $2.83.

A number of institutional investors have recently made changes to their positions in the business. Alpha Cubed Investments LLC acquired a new position in shares of Opko Health in the 3rd quarter valued at approximately $25,000. Eqis Capital Management Inc. bought a new stake in shares of Opko Health during the 2nd quarter worth approximately $33,000. Sawtooth Solutions LLC bought a new stake in shares of Opko Health during the 2nd quarter worth approximately $45,000. Kings Point Capital Management acquired a new stake in shares of Opko Health during the 2nd quarter worth approximately $45,000. Finally, GABELLI & Co INVESTMENT ADVISERS INC. boosted its position in shares of Opko Health by 100.0% during the 2nd quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 20,000 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 10,000 shares in the last quarter. Hedge funds and other institutional investors own 21.61% of the company’s stock.

Opko Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

Read More: Net Margin – Understanding the Different Kinds of Profit

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.